Drug research

Cabozantinib

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Cabometyx; Cabometyx®; XL-184; XL184

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Study of Cabozantinib (XL184) in Adults With Advanced MalignanciesNCT00940225	Exelixis	Phase 2	Completed	2013-05Actual
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyNCT03755791	Exelixis	Phase 3	Active not recruiting	2021-11-30Actual
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second RelapseNCT01068782	Exelixis	Phase 2	Terminated	2011-05Actual
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaNCT07011719	RCUS	Phase 3	Recruiting	2028-04Estimated
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaNCT03937219	Exelixis	Phase 3	Active not recruiting	2022-01-31Actual
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574	Exelixis	Phase 3	Enrolling by invitation	2030-05-31Estimated
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCNCT04446117	Exelixis	Phase 3	Active not recruiting	2024-04-19Actual
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted TherapyNCT03690388	Exelixis	Phase 3	Active not recruiting	2020-08-19Actual

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

ExelixisCompletedPrimary completion: 2013-05 · Actual

Trial details

Registry ID: NCT00940225
Phase: Phase 2

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy

ExelixisActive not recruitingPrimary completion: 2021-11-30 · Actual

Trial details

Registry ID: NCT03755791
Phase: Phase 3

Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

ExelixisTerminatedPrimary completion: 2011-05 · Actual

Trial details

Registry ID: NCT01068782
Phase: Phase 2

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

RCUSRecruitingPrimary completion: 2028-04 · Estimated

Trial details

Registry ID: NCT07011719
Phase: Phase 3

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

ExelixisActive not recruitingPrimary completion: 2022-01-31 · Actual

Trial details

Registry ID: NCT03937219
Phase: Phase 3

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

ExelixisEnrolling by invitationPrimary completion: 2030-05-31 · Estimated

Trial details

Registry ID: NCT07620574
Phase: Phase 3

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

ExelixisActive not recruitingPrimary completion: 2024-04-19 · Actual

Trial details

Registry ID: NCT04446117
Phase: Phase 3

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

ExelixisActive not recruitingPrimary completion: 2020-08-19 · Actual

Trial details

Registry ID: NCT03690388
Phase: Phase 3

Regulatory dates and decisions

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.